AR-R17779

Source: Wikipedia, the free encyclopedia.
AR-R17779
Names
IUPAC name
(2S)-4′-Azaspiro[bicyclo[2.2.2]octane-2,5′-[1,3]oxazolidin]-2′-one
Other names
(−)-Spiro[1-azabicyclo[2.2.2]octane-3,5′-oxazolidin-2′-one]
Identifiers
3D model (
JSmol
)
ChEBI
ChEMBL
ChemSpider
UNII
  • InChI=1S/C9H14N2O2/c12-8-10-5-9(13-8)6-11-3-1-7(9)2-4-11/h7H,1-6H2,(H,10,12)/t9-/m0/s1 checkY
    Key: TYAGAVRSOFABFO-VIFPVBQEBZ ☒N
  • InChI=1/C9H14N2O2/c12-8-10-5-9(13-8)6-11-3-1-7(9)2-4-11/h7H,1-6H2,(H,10,12)/t9-/m0/s1
  • O=C3O[C@]1(CN2CCC1CC2)CN3
Properties
C9H14N2O2
Molar mass 182.223 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

AR-R17779 is a drug that acts as a potent and selective

full agonist for the α7 subtype of neural nicotinic acetylcholine receptors.[1][2] It has nootropic effects in animal studies,[3][4] but its effects do not substitute for those of nicotine.[5] It has also been studied as a potential novel treatment for arthritis.[6]

References

  1. PMID 11063601
    .
  2. PMID 15357617
    .
  3. PMID 10780509
    .
  4. S2CID 23423717
    .
  5. PMID 10945867
    .
  6. PMID 19116908
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=AR-R17779&oldid=1059827784"